NIH K Awards in 2027: What NOT-OD-26-098 Changes and How to Prepare Now

What NOT-OD-26-098 Actually Does

NOT-OD-26-098 is a policy notice, not a guideline or a suggested change. That distinction matters: the changes it specifies are mandatory for applications submitted to funding opportunities with due dates on or after October 12, 2027. If your submission has a due date before that cutoff, you operate under current rules. If it falls on or after that date, you operate under the new ones.

The notice has three distinct components. First, it consolidates the dozens of institute-specific K award NOFOs into a streamlined set of parent NOFOs organized by K award program type — K01, K08, K23, K99/R00, and so on. Second, it ends NIH support for independent clinical trial conduct within K awards and eliminates the "Independent Clinical Trial Required" category of K funding opportunities. Third, it removes the Data Management and Sharing Plan requirement from K award applications altogether. Each piece deserves careful attention depending on your career stage and research focus.

NIH framed the changes as reducing administrative burden and improving consistency across institutes. That framing is accurate as far as it goes, but the clinical trial restriction is a substantive policy shift, not merely a paperwork reduction. Whether it affects you depends heavily on what kind of research you do and what you had planned to propose.

The NOFO Consolidation: Fewer Listings, Clearer Paths

If you've ever tried to find the right K award NOFO for your target institute, you know how fragmented the current landscape is. A K08 at NHLBI carries a different NOFO number than a K08 at NCI, and each one can include slightly different eligibility language, required form sections, or institute-specific added requirements. Applicants often spend considerable time confirming they have the right opportunity — and sometimes submit to the wrong one. The new parent NOFO structure will collapse these into program-type categories, with institutes opting in to each parent. You apply to the parent NOFO rather than hunting through institute-specific listings.

This consolidation is genuinely useful for applicants who are undecided between target institutes or applying to an institute where the current NOFO is difficult to locate. It also reduces the chance that you accidentally use an outdated institute-specific NOFO that doesn't reflect a recent policy change. For trainees early in the planning process, the new landscape should be meaningfully simpler to navigate.

The practical thing to check, once the parent NOFOs are finalized: confirm your target institute is participating. Not every institute is required to adopt the parent NOFO on day one, and some may maintain separate opportunities for institute-specific research priorities. Your program officer is the right person to ask once implementation details become clear closer to October 2027. For now, watch the NIH Guide for updated NOFO listings as the effective date approaches, and don't assume the parent NOFO covers every institute automatically.

Clinical Trials Are Out — With One Important Exception

This is the piece of NOT-OD-26-098 that most affects physician-scientists and translational researchers. Going forward, NIH will not fund K award mechanisms that require an independent clinical trial as part of the proposed research. K award funds cannot be used to support the conduct of a clinical trial, a clinical trial feasibility study, or an ancillary study to an existing clinical trial. The category called "Independent Clinical Trial Required" K award opportunities is being eliminated.

The important exception: K awardees can still participate in clinical trial research experiences that are led by their mentor or co-mentor. The restriction is on independently conducting a trial, not on being part of one under close supervision. If you're a K08 candidate in translational medicine, participating in a mentor-led trial as part of your training and career development plan remains a viable path. What you can't do under the new rules is propose a K award where you — the candidate — are the independent investigator running the trial.

For physician-scientists who had planned a K award with an independently conducted feasibility trial as the centerpiece of their mentored research, this is a real constraint that requires rethinking the application. Some may find that a K23 route now makes more sense as a mentored patient-oriented experience rather than an independent trial, while others may look to an R21 or a mentored role within an existing R01 in their lab. NIH is actively soliciting community input on how to structure clinical research experiences within the mentored K framework — the comment deadline is September 30, 2026, which is just ten days away as of this writing.

The Data Management and Sharing Plan Is Gone for K Awards

Since the NIH Data Management and Sharing Policy took effect in January 2023, K award applicants have been required to include a DMSP with their applications. That requirement is ending for K awards submitted on or after October 12, 2027. NIH's reasoning is that K awards are fundamentally training and career development grants, not data-generating research programs in the same sense as an R01. The mentored training focus makes a formal DMSP less applicable than it is for investigator-initiated research.

If you're currently preparing a K application for any 2026 or early 2027 cycle, you still need to include a DMSP. Don't drop it based on this notice until the effective date actually applies to your submission. Reviewers are still scored against the current requirements until October 2027, and omitting a required section will cause administrative issues at submission.

One thing worth keeping in mind for the longer arc of your career: when you transition from your K award to an R01, the DMSP requirement comes back in full. Your mentored years are exempt; your independent investigator years are not. Build good data management practices during the K period even if you're not formally required to write the plan — reviewers on your eventual R01 will expect evidence you've thought seriously about data sharing, and the habits you build now are the foundation for that section later.

The September 30 Comment Window

NIH has opened a public comment period specifically about how clinical trial research experiences should be structured within mentored K awards going forward. Comments are due September 30, 2026. That's a short window — ten days from the date of this post — and it's worth taking seriously if you work at the intersection of clinical research and career development training, or if you mentor K award candidates whose research involves patients.

NIH doesn't hold these feedback windows as formalities. The fact that they're specifically soliciting input on clinical trial experiences within the mentored framework suggests this policy area isn't fully locked down. Your perspective as a physician-scientist trainee, an active K awardee, or a mentor who coordinates these experiences is exactly what the solicitation is designed to capture. Check the NOT-OD-26-098 notice directly for the submission link and format guidance. For most NIH comment requests of this type, a focused one- to two-page statement with a clear position and the specific concern or suggestion behind it carries more weight than a lengthy general critique.

Adjusting Your K Award Timeline for 2027

The effective date tied to application due dates on or after October 12, 2027 creates a meaningful planning window. Standard K award due dates fall in February, June, and October each year. Applications due in February 2027 and June 2027 are under current rules. The first affected cycle is October 2027. If you have a choice between submitting in June 2027 versus October 2027, that choice now depends partly on whether the old or new rules better fit your project.

For most basic researchers, the new rules are unlikely to change your strategy in any material way. The DMSP removal is a modest burden reduction, the NOFO consolidation helps navigation, and the clinical trial restriction doesn't apply to bench research. For physician-scientists, the calculation is different. If your proposed K award currently involves an independent clinical trial component, submitting under the old rules in the June 2027 cycle preserves a path that closes in October 2027.

That said, approach the timing question carefully. Reviewers on K applications are looking for a coherent career development plan that fits the mentored nature of the mechanism. If the best version of your science genuinely involves a mentor-led clinical research experience rather than an independent trial, the new rules may actually align better with the K mechanism's purpose than the older framework did. Rushing a June 2027 submission to preserve an independent trial option that doesn't fit your science is rarely worth it. Your program officer can help you think through whether the restriction actually changes what you can propose.

Frequently Asked Questions